Related Experiment Video
Updated: Jun 27, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Comprehensive bioinformatics analysis of NOX4 as a biomarker for pan-cancer prognosis and immune infiltration
Yuying Liu1, Hua Huang2, Xijun Yang3
1Department of Pathology, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Nanjing, China.
Background:
NADPH oxidase 4 (NOX4) has been proven to be associated with the prognosis of tumors in multiple cancers and can serve as a potential immunotherapy target to provide new treatment options for various tumors. In this study, our aim is to conduct an in-depth investigation of NOX4 across a range of cancer types to determine the relationship between NOX4 and tumors.
Methods:
Utilizing large-scale transcriptomic and clinical data from public databases, a systematic examination of NOX4 expression patterns was performed in pan-cancer cohorts. Survival analysis, methylation analysis, and correlation studies were employed to assess the diagnostic and prognostic significance of NOX4 in diverse cancer types. Additionally, an exploration of the relationship between NOX4 expression and immune infiltration across various tumors was conducted.
Results:
The analyses unveiled a consistent upregulation of NOX4 expression in multiple cancer types relative to normal tissues, indicating its potential as a universal cancer biomarker. Elevated NOX4 expression significantly correlated with poor overall survival in several cancers. Furthermore, the study demonstrated a robust correlation between NOX4 expression and immune cell infiltration, signifying its involvement in the modulation of the tumor microenvironment.
Conclusions:
This study imparts valuable insights into the potential applications of NOX4 in cancer research, highlighting its significance as a multifaceted biomarker with diagnostic, prognostic, and immunomodulatory implications across diverse malignancies.
Insights
NADPH oxidase 4 (NOX4) is upregulated in many cancers and linked to poor survival. This NOX4 biomarker shows potential for cancer diagnosis, prognosis, and immunotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- NADPH oxidase 4 (NOX4) is implicated in tumor prognosis and represents a potential immunotherapy target.
- Understanding NOX4's role across various cancers is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To comprehensively investigate NOX4 expression patterns and its association with tumor characteristics in pan-cancer cohorts.
- To evaluate the diagnostic and prognostic value of NOX4.
- To explore the relationship between NOX4 and immune infiltration in the tumor microenvironment.
Main Methods:
- Analysis of large-scale transcriptomic and clinical data from public databases.
- Pan-cancer survival analysis, methylation analysis, and correlation studies.
- Assessment of NOX4 expression in relation to immune cell infiltration.
Main Results:
- NOX4 expression is consistently upregulated in multiple cancer types compared to normal tissues.
- Elevated NOX4 levels correlate significantly with poorer overall survival in several cancers.
- A strong association exists between NOX4 expression and immune cell infiltration, indicating its role in modulating the tumor microenvironment.
Conclusions:
- NOX4 serves as a potential pan-cancer biomarker with diagnostic and prognostic capabilities.
- NOX4 expression is linked to immune infiltration, suggesting its immunomodulatory role in malignancies.
- These findings highlight NOX4's multifaceted significance in cancer research and its potential as a therapeutic target.
More Related Videos
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024